Will Regenxbio (RGNX) Report Negative Earnings Next Week? What You Should Know

Company Overview - Regenxbio (RGNX) is expected to report a year-over-year increase in earnings driven by higher revenues for the quarter ended December 2024, with a consensus estimate of a quarterly loss of $1.27 per share, reflecting an 11.2% improvement from the previous year [1][3] - Revenues are projected to reach $22.9 million, which is a 3.1% increase compared to the same quarter last year [3] Earnings Estimates and Revisions - The consensus EPS estimate has been revised 20.37% higher in the last 30 days, indicating a reassessment by analysts regarding the company's earnings prospects [4] - The Most Accurate Estimate for Regenxbio is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1.58%, suggesting a bearish outlook from analysts [10][11] Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict the likelihood of actual earnings deviating from consensus estimates, with a positive ESP being a strong predictor of an earnings beat [6][8] - Regenxbio's combination of a negative Earnings ESP and a Zacks Rank of 2 (Buy) complicates the prediction of an earnings beat [11] Historical Performance - In the last reported quarter, Regenxbio was expected to post a loss of $1.16 per share but actually reported a loss of $1.17, resulting in a surprise of -0.86% [12] - Over the past four quarters, the company has only beaten consensus EPS estimates once [13] Industry Context - Another player in the biomedical sector, scPharmaceuticals, is expected to report an EPS of $0.40 for the same quarter, which represents a year-over-year decline of 14.3%, with revenues expected to be $12.08 million, up 98% from the previous year [17] - The consensus EPS estimate for scPharmaceuticals has been revised 26.3% lower in the last 30 days, but a higher Most Accurate Estimate has resulted in an Earnings ESP of 2.50%, despite a Zacks Rank of 4 (Sell) [18]